As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This RFI response, submitted by ACRO to the FDA in June 2026, on a proposed pilot program to assess how artificial intelligence (AI)-enabled technologies can improve efficiency, speed, and quality of decision-making in early phase clinical trials, can be found below.